



RESEARCH TOPIC CLI31

Real-life effectiveness of biological drugs for chronic rhinosinusitis with nasal polyps: from single outcomes to clinical remission

Research Area

Medical Area

Clinical Unit name

Personalized Medicine, Asthma and Allergy – IRCCS Humanitas Research Hospital

Supervisor

Enrico Heffler

Abstract

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory disease for which several biological drugs are available, all of which have type 2 inflammation as molecular targets. The efficacy of these drugs has been proven by placebo-controlled randomized clinical trials, while there are still few descriptions of their effectiveness in real-life. The research project will evaluate different aspects of the real-life effectiveness of biological drugs for CRSwNP, considering the response in terms of individual outcomes (reduction in the endoscopic and radiological extension of the disease, improvement in quality of life, reduction in the use of systemic corticosteroids...), including inflammatory ones and search for predictive biomarkers. The achievement of clinical remission will also be evaluated (multiple outcomes obtained simultaneously and for a prolonged period in the individual patient). Prospective, observational study, duration: 3 years.

Scientific references

1. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19. Erratum in: *Lancet*.
2. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. *J Allergy Clin Immunol*. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032.

3. Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, Tversky JR, Barker P, Cohen D, Emson C, Martin UJ, Shih VH, Necander S, Kreindler JL, Jison M, **Werkström V**. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2022 Apr;149(4):1309-1317.e12. doi: 10.1016/j.jaci.2021.08.030.
4. Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med*. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7.
5. Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P, Scadding GK, Wagemann M, Bernal-Sprekelsen M, Chaker A, Heffler E, Han JK, Van Staeyen E, Hopkins C, Mullol J, Peters A, Reitsma S, Senior BA, Hellings PW. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. *Rhinology*. 2023 Jun 1;61(3):194-202.
6. Paoletti G, Casini M, Malvezzi L, Pirola F, Russo E, Nappi E, Muci GQ, Montagna C, Messina MR, Ferri S, Racca F, Lamacchia D, Cataldo G, Puggioni F, De Virgilio A, Ferrelì F, Mercante G, Spriano G, Canonica GW, Heffler E. Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab. *J Invest Allergol Clin Immunol*. 2023 Dec;33(6):457-463. doi: 10.18176/jiaci.0851.
7. Ferri S, Montagna C, Casini M, Malvezzi L, Pirola F, Russo E, Racca F, Messina MR, Puggioni F, Nappi E, Costanzo G, Del Moro L, Mercante G, Spriano G, Canonica GW, Paoletti G, Heffler E. Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by dupilumab. *Ann Allergy Asthma Immunol*. 2024 Jan;132(1):69-75. doi: 10.1016/j.anai.2023.08.594.

Type of contract

Position not supported by any scholarship or equivalent contract.